Status: Not yet recruiting
Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning
Because the anti-leukemic activity of busulfan, this dug is largely used in graft conditioning but in elderly and/or cormobid patienth an excess of toxicity is observed. This study focus on the possibility of significanty reducing this toxicity by customizing the doses of busulfan to individual PK parameters.
Participants needed: 82
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Institut Paoli-CalmettesUpdated: Nov 17, 2020
Eligibility criteria
Adult patient up to 65 years old [+5]
Pregnant woman, without effective contraception or breastfeeding [+5]